Lataa...
The role of combined fludarabine, cyclophosphamide and rituximab chemoimmunotherapy in chronic lymphocytic leukemia: current evidence and controversies
Chemoimmunotherapy (CIT) has become a cornerstone in the treatment of patients with chronic lymphocytic leukemia (CLL). The combination of fludarabine, cyclophosphamide and rituximab (FCR) has emerged as the standard of care for therapy of previously untreated patients with CLL who are younger than...
Tallennettuna:
| Julkaisussa: | Ther Adv Hematol |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
SAGE Publications
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5305006/ https://ncbi.nlm.nih.gov/pubmed/28246553 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620716681749 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|